IP Library Granted Patent US 9,987,321
Granted Patent B2
US 9,987,321 · App. 14/083,804 · Granted Jun 5, 2018

Use of flaxseed and flaxseed derivatives for treatment of neurological disorders and viral diseases

Inventors: Melpo Christofidou-Solomidou (Eagleville, PA); Kelly Jordan-Sciutto (Lansdale, PA)
Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
A61K36/55A61K31/05A61K31/365A61K31/70
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,987,321
App. No.
14/083,804
Granted
Jun 5, 2018
Kind
B2
Abstract

The invention provides compositions and methods for treating neurological disorders and viral infection using whole-grain flaxseed, flaxseed lignans such as Secoisolariciresinol diglucoside (SDG), human lignans metabolized from flaxseed such as Enterodiol (ED) or Enterolactone (EL), and synthetic flaxseed lignan analogs.

Claims (8)

1. A method for treating infection-mediated neuronal damage in a subject having infection-mediated neuronal damage comprising the step of administering to said subject a therapeutically effective amount of a lignan, wherein said lignan is a flaxseed lignan selected from the group consisting of a flaxseed lignan complex (FLC) and secoisolariciresinol diglucoside (SDG).

2. The method of claim 1 , wherein said lignan is administered in the form of a flaxseed lignan complex (FLC).

3. The method of claim 1 , wherein said lignan is a flaxseed lignan and said flaxseed lignan is secoisolariciresinol diglucoside (SDG).

4. The method of claim 1 , wherein said step of administering comprises oral administration.

5. The method of claim 1 , wherein said infection is a viral infection or a bacterial infection.

6. The method of claim 5 , wherein said subject is a human and said infection is human immunodeficiency virus (HIV) infection.

7. The method of claim 6 , wherein said subject is receiving antiretroviral therapy.

8. The method of claim 6 , wherein said subject is diagnosed with HIV-associated Neurocognitive Disorder (HAND).

Assignments (2)
CONFIRMATORY LICENSE Recorded Jun 9, 2016
From: UNIVERSITY OF PENNSYLVANIA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 038926/0341 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 1, 2015
From: CHRISTOFIDOU-SOLOMIDOU, MELPO; JORDAN-SCIUTTO, KELLY
To: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Reel/Frame 035755/0706 →
Continuity (3)
Provisional Application 61728476 · Nov 20, 2012
Provisional Application 61789986 · Mar 15, 2013
Related Publication 20140308379A1 · Oct 16, 2014